PFE · Categories · Downgrades
PFE - Analyst downgrades
Pfizer Inc. (PFE) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for PFE
- Pfizer downgraded by Daiwa Securities with a new price targetDaiwa Securities downgraded Pfizer from Outperform to Neutral and set a new price target of $27.00
- Pfizer downgraded by ArgusArgus downgraded Pfizer from Buy to Hold
- Pfizer downgraded by TD Cowen with a new price targetTD Cowen downgraded Pfizer from Outperform to Market Perform and set a new price target of $32.00
- Pfizer downgraded by Credit Suisse with a new price targetCredit Suisse downgraded Pfizer from Outperform to Neutral and set a new price target of $40.00 from $47.00 previously
- Pfizer downgraded by Daiwa Securities with a new price targetDaiwa Securities downgraded Pfizer from Outperform to Neutral and set a new price target of $38.00
- Pfizer downgraded by UBS with a new price targetUBS downgraded Pfizer from Buy to Neutral and set a new price target of $47.00 from $55.00 previously
- Pfizer downgraded by Wells Fargo with a new price targetWells Fargo downgraded Pfizer from Overweight to Equal Weight and set a new price target of $50.00 from $54.00 previously
- Pfizer downgraded by BofA Securities with a new price targetBofA Securities downgraded Pfizer from Buy to Neutral and set a new price target of $60.00
- Pfizer downgraded by Mizuho with a new price targetMizuho downgraded Pfizer from Buy to Neutral and set a new price target of $42.00